AVTX Jonathan Goldman sells $163K worth of shares
Nov 18, 2025, 5:36 AM
0.00%
What does AVTX do
Avalo Therapeutics, a clinical-stage biotechnology company headquartered in Rockville, Maryland, focuses on immune dysregulation therapies, with key assets including AVTX-009, quisovalimab, and AVTX-008. The company went public on November 13, 2015, and employs 19 people.
Jonathan Goldman sold 11,367 shares of AVTX on 14 November at $14.35 per share, worth a total of $163K. They now own 0 AVTX shares, or a 100% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.